

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/559,982
				Filing Date	February 2, 2006
				First Named Inventor	Ruggero Fariello
				Group Art Unit	1617
				Examiner Name	Sahar JAVANMARD
Confirmation No.	6583				
Sheet	1	of	2	Attorney Docket No.	373987-011US (102895)

U.S. PUBLISHED DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Publication Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	A8	US-5,391,577		Dostert <i>et al.</i>	02-21-1995
	A9	US-5,945,454		Pevarello <i>et al.</i>	08-31-1999

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ²	
		Office	Number	Kind Code (if known)			Yes	No
	B5	EP	0400495	A1	12-05-1990	Farmitalia Carlo Erba S.r.L.		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ²	
			Yes	No
	C19	ANONYMOUS: "Newron Releases Positive Preliminary Phase II Data for Salfinamide in Parkinson's Disease" PRESS RELEASE OF 01-09-2003, Retrieved from the Internet: <URL: http://www.newron.com/uploads/SafinamidePhaseIIdataFinal090103.pdf retrieved on 02-18-2009		
	C20	Communication for European Patent Application 04 726 590.5-2123 mailed 12-05-2006		
	C21	International Preliminary Examination Report and Written Opinion of PCT/IB2004/001408		
	C22	International Search Report of PCT/IB2004/001408		
	C23	Letter regarding Oral Proceedings for European Patent Application 04 726 590.5-2123 dated 10-19-2007		
	C24	Minutes of Oral Hearing (01-25-2008) for EP 04 726 590.5-2123		

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/559,982
				Filing Date	February 2, 2006
				First Named Inventor	Ruggero Fariello
				Group Art Unit	1617
				Examiner Name	Sahar JAVANMARD
				Confirmation No.	6583
Sheet	2	of	2	Attorney Docket No.	373987-011US (102895)

	C25	Reply to Examination Report for European Patent Application 04 726 590.5-2123 dated 08-09-2006		
	C26	Reply to Examination Report for European Patent Application 04 726 590.5-2123 dated 04-06-2007		
	C27	Stocchi, F. <i>et al.</i> , 2006, "Symptom Relief in Parkinson Disease by Safinamide: Biochemical and Clinical Evidence of Efficacy beyond MAO-B Inhibition; <i>Neurology</i> 67(7)SUPPL2:S24-S29		
	C28	Stocchi F. <i>et al.</i> , 2004, "Improvement of Motor Function in Early Parkinson Disease by Safinamide," <i>Neurology</i> 63(4):746-748		
	C29	Summons to Attend Oral Hearings for European Patent Application 04 726 590.5-2123 dated 07-02-2007		

15106978.1.BUSINESS

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or translation of abstract is attached.